Latest valproic acid Stories
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy â€“ the most common form of epilepsy in kids â€“ has established an evidence-based approach for initial drug therapy.
RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
Embryonic stem (ES) cells, known for their capacity to proliferate indefinitely and differentiate into almost all types of cells including hepatocytes, have raised the hope of cellular replacement therapy for liver failure.
REHOVOT, Israel, November 9 /PRNewswire-FirstCall/ -- D-Pharm Ltd. (TASE: DPRM) announced today that it has entered into a licensing, co-development and supply agreement with Wanbang Biopharmaceuticals Ltd. for commercialization of DP-b99 in the People's Republic of China.
Pregnant women are advised to take vitamin supplements containing folic acid as part of their routine pre-natal care.
Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities.
REHOVOT, Israel, August 17 /PRNewswire/ -- D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company's late stage clinical stroke program.
Scientists at Leeds have prevented epilepsy caused by a gene defect from being passed on to mice offspring â€“ an achievement which may herald new therapies for people suffering from the condition.
Interim results of a study being conducted by scientists at the University of Liverpool suggest that children aged three years and younger, who are born to women taking the anti-epileptic drug sodium valproate whilst pregnant
SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, today announced it has closed a $60 million Series C financing.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.